Samsara Total Cost of Revenue increased by 9.2% to $105.92M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 31.9%, from $80.30M to $105.92M. Over 4 years (FY 2022 to FY 2026), Total Cost of Revenue shows an upward trend with a 31.9% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $25.63M | $28.37M | $31.78M | $38.71M | $39.62M | $44.26M | $47.25M | $51.53M | $57.56M | $58.87M | $61.59M | $69.02M | $68.63M | $73.37M | $76.03M | $80.30M | $83.17M | $90.50M | $96.96M | $105.92M |
| QoQ Change | — | +10.7% | +12.0% | +21.8% | +2.4% | +11.7% | +6.8% | +9.0% | +11.7% | +2.3% | +4.6% | +12.1% | -0.6% | +6.9% | +3.6% | +5.6% | +3.6% | +8.8% | +7.1% | +9.2% |
| YoY Change | — | — | — | — | +54.6% | +56.0% | +48.7% | +33.1% | +45.3% | +33.0% | +30.3% | +34.0% | +19.2% | +24.6% | +23.5% | +16.3% | +21.2% | +23.4% | +27.5% | +31.9% |